Previous Article | Next Article 
J Virol, February 1998, p. 1424-1430, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Entry of Amphotropic and 10A1 Pseudotyped Murine Retroviruses
Is Restricted in Hematopoietic Stem Cell Lines
Dorothee
von
Laer,1,*
Silke
Thomsen,1
Birgit
Vogt,1
Martina
Donath,2
Joachim
Kruppa,2
Alan
Rein,3
Wolfram
Ostertag,1 and
Carol
Stocking1
Heinrich-Pette-Institut für Experimentelle Virologie
und Immunologie an der Universität Hamburg, 20251 Hamburg,1 and
Institut für
Physiologische Chemie, Universität Hamburg, 20146 Hamburg,2 Germany, and
Laboratory of
Molecular Virology and Carcinogenesis, Advanced Bioscience
Laboratories, Basic Research Program, National Cancer Institute
Frederick Cancer Research and Development Center, Frederick, Maryland
21702-12013
Received 17 July 1997/Accepted 30 October 1997
 |
ABSTRACT |
Although transduction with amphotropic murine leukemia virus (MLV)
vectors has been optimized successfully for hematopoietic differentiated progenitors, gene transfer to early hematopoietic cells
(stem cells) is still highly restricted. A similar restriction to gene
transfer was observed in the mouse stem cell line FDC-Pmix compared with transfer in the more mature myeloid precursor cell line FDC-P1 and the human erythroleukemia cell line K562. Gene transfer
was not improved when the vector was pseudotyped with gp70SU of the 10A1 strain of MLV, which uses the receptor
of the gibbon ape leukemia virus (Pit1), in addition to the
amphotropic receptor (Pit2). Although 10A1 and amphotropic
gp70SU bound to FDC-P1, K562, and fibroblasts, no binding
to FDC-Pmix cells was detected. This indicates that FDC-Pmix cells
lack functional Pit2 and Pit1 receptors. Pseudotyping with the
vesicular stomatitis virus G protein improved transduction efficiency
in FDC-Pmix stem cells by 2 orders of magnitude, to fibroblast
levels, confirming a block to retroviral infection at the receptor
level.
 |
INTRODUCTION |
The hematopoietic stem cell with
long-term reconstitution ability is a target for gene therapy. However,
the efficiency of gene transfer to stem cells with murine leukemia
virus (MLV) vectors packaged as amphotropic pseudotypes is extremely
poor (8). In clinical protocols and in studies on large
mammals, fewer than 1% of the peripheral blood leukocytes contain the
transgene after transplantation of transduced hematopoietic
progenitors (6, 12, 36).
More detailed analysis of gene transfer to stem cells has been
difficult. Stem cells comprise a very small population in the bone marrow, and their exact phenotype is not known. Thus, the purity of stem cell preparations is generally low and their analysis is
restricted to small cell numbers. The frequency of SCID repopulating cells was estimated to be 1 in 600 CD34+ CD38
cells (21), and that of mouse repopulating cells in the
Sca-1+ c-Kit+ lin
bone marrow population is about 1 in 100 (28).
To analyze the mechanisms that limit retroviral gene transfer to
hematopoietic stem cells, we therefore chose the stem cell line
FDC-Pmix, which shows factor-dependent growth (7, 15). These
cells are the closest available in vitro equivalent to
hematopoietic stem cells. As a comparison, the more mature
granulocyte-macrophage precursor cell line FDC-P1 and the
human erythroleukemia cell line K562 were analyzed. Gene transfer
with amphotropic vectors is highly restricted in the hematopoietic stem
cell line FDC-Pmix and more efficient in FDC-P1 (5, 17).
This is in accordance with primary progenitor cells, where transduction
efficiency is higher in more mature progenitors than in primary
multipotent hematopoietic stem cells (21).
A possible explanation for the restricted gene transfer to stem
cells is that MLV infects only cycling cells while the nuclear transport of the preintegration complex is inhibited in quiescent cells (34). Most stem cells do not cycle
(1). However, transduction of FDC-Pmix cells, which
actively cycle, is also restricted, indicating that there are
additional limitations to transduction in early cells. A
restriction at the level of retroviral transcription could explain the
low transfer efficiency. Indeed, we have previously found
that expression of vectors derived from the Moloney strain of
MLV, which are most frequently used, is poor in hematopoietic progenitors. However, this restriction can be eliminated by using chimeric vectors in which the long-terminal repeat is derived from either the polycythemia strain of Friend spleen focus-forming virus or the myeloproliferative sarcoma virus and the
downstream leader sequence is derived from the murine embryonal
stem cell virus (MESV) (3, 13). These vectors do
not limit transduction at the level of expression.
In previous studies, we have shown that infection of FDC-Pmix with
amphotropic MLV is also restricted before synthesis and integration of
proviral DNA, i.e., at the level of vector binding, penetration, or
reverse transcription (5). Infection efficiency with
ecotropic MLV could not be studied, since FDC-Pmix cells contain an
interfering ecotropic virus. Here, we analyzed the restriction for
amphotropic MLV in more detail. We tested if virus binding to the
amphotropic receptor Pit2 was restricted and if transduction efficiency
could be improved by pseudotypes that enter the cell by other
receptors. A vector pseudotyped with the gp70SU of the 10A1
strain of MLV was studied. This virus utilizes the amphotropic receptor
(Pit2), as well as the receptor for the gibbon ape leukemia virus
(GALV) (Pit1) (25, 29). The latter receptor is highly
expressed in bone marrow cells (20). Moreover, 10A1 MLV
induces stem cell leukemia in mice (31). It has been
suggested that pseudotyping with the 10A1 env may
improve gene transfer to hematopoietic stem cells (20). Here
we show that neither amphotropic nor 10A1 MLV gp70SU
binds to FDC-Pmix cells at detectable levels and that gene
transfer in FDC-Pmix cells with 10A1 pseudotypes is also restricted. In contrast, transduction was improved greatly with vesicular stomatitis virus (VSV) G-protein pseudotypes of MLV. These data indicate that
transduction with 10A1 and amphotropic MLV is limited at the level of
virus binding and possibly penetration.
 |
MATERIALS AND METHODS |
Cells and retroviral vectors.
The cell lines used for
infection include the mouse factor-dependent myeloid cell line FDC-P1,
the mouse factor-dependent hematopoietic stem cell lines FDC-Pmix, and
the human erythroleukemia cell line K562 (7, 10). Two
independent isolates of FDC-Pmix were used: A4, which has multipotent
differentiation capacity in erythroid and myeloid lineages, and 15s,
which has lost its differentiation capacity. Additionally, the mouse
fibroblast cell lines SC-1 (ATCC CRL-1404), NIH 3T3, and L929 were
used. Fibroblasts and FDC-P1 cells were maintained in minimal essential
medium (Sigma, Deisenhofen, Germany) supplemented with 10% fetal calf
serum (PAN Systems, Aidenbach, Germany). FDC-Pmix and FDC-P1 cells were
maintained in Iscove's modified Dulbecco's medium (Gibco, Paisley,
Great Britain) supplemented with 20% horse serum. Conditioned medium from cells transfected with a bovine papillomavirus vector carrying the
interleukin-3 gene was used as a source of interleukin-3 at concentrations necessary for maximum stimulation of FDC-P1 and FDC-Pmix
cells (19). K562 cells were maintained in RPMI 1640 (Gibco)
supplemented with 10% fetal calf serum.
All the vectors used for these studies were based on the Friend
spleen focus-forming virus/MESV (SF1N) or myeloproliferative sarcoma virus/MESV (MPEVneo) chimeric vectors carrying
neo, which have been described previously (13).
Replication-competent Moloney MLV recombinants, in which part of the
pol gene and most of the env gene were replaced
with those from either MLV 4070A (Mo-Ampho-MP, R320
[26]) or 10A1 (Mo-10A1 [30]) as a
SalI-ClaI fragment, were used for binding assays
and for pseudotyping of vectors. Virus was propagated in SC-1. The
amphotropic packaging cell line GP+Am12 was used to generate
amphotropic SF1N (22).
Transduction efficiency.
To determine transduction
efficiencies, 12-h virus supernatants were collected. A total of
106 cells per well were inoculated with serial dilutions of
the supernatant. Plates were centrifuged for 1 h at 900 × g at room temperature and incubated at 37°C for a further
12 h. Since Polybrene and protamine sulfate were found to improve
transduction efficiency in fibroblasts but not in FDC-Pmix cells (data
not shown), a polycation was not used. After infection, fibroblasts
were trypsinized and hematopoietic cells were washed twice in
phosphate-buffered saline (PBS). Fibroblasts were plated at
concentrations ranging from 1 × 101 to 3 × 104 cells per dish and selected with medium containing G418
(0.4 mg [dry weight] per ml; GIBCO). Hematopoietic cells were plated in agar (0.3%) cultures containing G418 (1 mg [dry weight] per ml).
The cell concentrations ranged from 3 × 101 to 3 × 103, and 3 × 105 cells per dish. After
10 days of incubation, duplicate cultures were scored for colony
formation. In parallel, cloning efficiency was determined in the
absence of G418. Transduction efficiency was calculated as the ratio of
colonies grown in the presence of G418 to colonies grown without
selection. The titer was calculated from the transduction efficiencies
in SC-1. Only virus dilutions below the level of saturation were
included in the calculation. The multiplicity of infection (MOI) was
determined from the vector titer on SC-1 cells and is expressed as G418
resistance transfer units (GTU) per milliliter.
Binding assay.
The gp70SU binding assay
was performed as described by Kadan et al. (18). For
amphotropic virus, monoclonal antibody 83A25 (14)
followed by a biotinylated goat anti-rat antibody (Pharmingen, Hamburg, Germany) was used. For the 10A1 strain, a goat antiserum to MLV gp70 (35) followed by a biotinylated donkey
anti-goat antibody (Laboserv, Giessen, Germany) was used. In both
cases, cells were stained with streptavidin-phycoerythrin
(Pharmingen). Cells (106 cells per sample) were
harvested by brief trypsinization (necessary only for fibroblasts),
rinsed with serum-containing medium, and resuspended in 1 ml of virus
supernatant. After an incubation of 45 min at 4°C, the cells were
washed three times with 2 ml of ice-cold PBS with 5% fetal calf serum.
The cells were resuspended in 50 µl of the first antibody and
incubated on ice for 30 min. They were then washed three
more times, resuspended in 50 µl of the secondary
antibody, and incubated on ice for another 30 min. After the next
washing, the cells were incubated with 50 µl of streptavidin-phycoerythrin on ice for 10 min, washed, and finally fixed
in 500 µl of PBS with 1% paraformaldehyde. Following
gp70SU binding and antibody staining, cell samples were
analyzed for fluorescence intensity on a flow cytometer (FACScalibur;
Becton Dickinson, Heidelberg, Germany).
Packaging cell line for VSV G-protein-pseudotyped retroviral
vectors.
Moloney MLV gag and pol were cloned
as an EcoRI-HindIII fragment into pSBC-2
under the control of the simian virus 40 promoter (11). This
pSBC-gp plasmid was cotransfected with a plasmid containing the
hygromycin resistance gene into 293 cells. After selection with 100 µg of hygromycin per ml, cell clones were analyzed by flow cytometry
for intracellular p30 expression. The clone 293gp2 with high p30
expression was transduced with SF1N carrying the neo gene,
which had been packaged in GP+Am12 (22). After selection
with 200 µg of G418 per ml, clones were subjected to calcium
phosphate transfection with the plasmid pSNJG expressing the G protein
of the New Jersey strain of vesicular stomatitis virus (VSV) (cloned
from pNJG6 into pSG [16]) under the control of the
simian virus 40 promoter in pSG. Supernatants could be harvested daily
for 1 week. The titers ranged from 104 to 105
GTU/ml for the cell clone SF23 used in this study.
 |
RESULTS |
Insufficient transduction of multipotent hematopoietic cells with
amphotropic pseudotypes.
Initially, the transduction efficiencies
were compared among the mouse fibroblast cell lines SC-1, NIH 3T3, and
L929 cells by using a retroviral vector containing neo with
an amphotropic murine leukemia virus (A-MLV) helper at different MOIs
(determined on SC-1). The results are shown in Fig.
1. The portion of transduced cells
(transduction efficiency) increased linearly with rising MOI and
leveled off at an MOI between 0.1 and 1 GTU/cell. Although SC-1 and NIH
3T3 cells tended to be slightly more susceptible than L929 cells, the
transduction efficiencies did not differ by more than sixfold between
the different fibroblast cell lines. SC-1 cells were then used as a
standard for transduction experiments throughout the rest of this
study.

View larger version (28K):
[in this window]
[in a new window]

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Transduction of fibroblasts and hematopoietic
progenitor cell lines with an A-MLV vector. Fibroblasts and
hematopoietic cell lines were transduced at different MOIs with a
retroviral vector containing neo packaged by an amphotropic
helper virus. Transduction efficiencies were calculated as the ratio of
G418-resistant cell clones to the number of unselected clones.
Solid circles, SC-1 fibroblasts; open squares, NIH 3T3 cells; open
triangles, L929 cells; open circles, cell line mentioned in the figure.
|
|
The efficiency of retroviral transfer to hematopoietic
progenitor cell lines was analyzed in comparison to
fibroblasts. Several
MOIs were tested. If cells are heterogeneous
and bind virus with
different affinities, a nonlinear correlation of
the MOI to the
portion of cells transfected would have been
expected. In the
mouse stem cell lines FDC-Pmix A4 and FDC-Pmix 15s,
transduction
efficiencies were approximately 100-fold lower than in
fibroblasts
at all MOIs tested. No clear subpopulation that was
more susceptible
to transduction could be discerned. The mouse
myeloid cell line
FDC-P1, representing a more mature
hematopoietic precursor, could
be readily transduced at low MOIs, while
transduction was reduced
at higher MOIs. This indicates that a fraction
of cells was fully
susceptible. K562, a human erythroleukemia cell
line, was efciently
transduced at all MOIs (Fig.
1). Thus,
transduction was reduced
in the immature stem cell lines compared to
the more mature hematopoietic
cell lines and fibroblasts. These results
are in agreement with
data for primary hematopoietic cells, where
transduction efficiencies
are lowest in the most immature hematopoietic
stem cells and improve
as the cells differentiate (
21). We
therefore conclude that
FDC-Pmix cells are a useful system to develop
strategies for improving
gene transfer to hematopoietic stem cells.
10A1 pseudotypes do not improve transfer efficiency to
FDC-Pmix cells.
Pseudotypes of MLV that use receptors other
than Pit2 were tested for their ability to overcome a possible
restriction of virus entry in FDC-Pmix stem cells. The 10A1 strain of
MLV uses the GALV receptor (Pit1) as well as the amphotropic receptor
(Pit2) for entry into human and NIH 3T3 mouse fibroblasts
(23). Using interference studies, we found that 10A1 can
also enter SC-1 cells via either of these two receptors (data not
shown). SC-1 cells are derived from wild mice. 10A1 also most probably
uses Pit1 for entry into cells of other mouse strains including
DBA/2 and B6D2F1, from which FDC-Pmix and FDC-P1 cells, respectively,
were isolated.
We transduced FDC-Pmix, FDC-P1, and K562 by using a
neo
vector packaged in 10A1 gp70
SU. However, as with
amphotropic pseudotypes, transduction was reduced
by more than 100-fold
in stem cells but was nearly equivalent
to fibroblast transduction
efficiency in the more mature hematopoietic
cell lines (Fig.
2). Transduction of hematopoietic stem
cells
therefore could not be improved with the 10A1 strain of MLV. In
conclusion, transduction in FDC-Pmix is restricted for both 10A1
and
amphotropic pseudotyped vectors.

View larger version (28K):
[in this window]
[in a new window]

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Transduction of fibroblasts and hematopoietic progenitor
cell lines with an MLV vector, pseudotyped with the surface proteins of
10A1. Fibroblasts and hematopoietic cell lines were transduced at
different MOIs with a retroviral vector containing neo
packaged by a 10A1 helper virus. Transduction efficiencies were
calculated as the ratio of G418-resistant cell clones to the number of
unselected clones. Solid circles, SC-1 fibroblasts; open squares, NIH
3T3 cells, open circles, cell line mentioned in the figure.
|
|
No detectable binding of amphotropic and 10A1 gp70SU to
FDC-Pmix.
In a previous study, we have shown that A-MLV infection
of FDC-Pmix stem cells was restricted early during infection, at the level of virus binding, penetration, or reverse transcription (5). To investigate this restriction further, we analyzed
the binding of amphotropic and 10A1 gp70SU to fibroblasts
and different hematopoietic progenitor cell lines by a flow cytometric
assay. Cells were incubated with virus supernatants, and binding of
virus and soluble surface glycoprotein gp70SU was detected
with an antibody to gp70 (Fig. 3).
Binding to fibroblasts such as NIH 3T3 and SC-1 cells and the human
hematopoietic cell line K562 was high. Binding to FDC-P1 was much lower
but still detectable. In contrast, binding was never detected for the
two hematopoietic stem cell lines FDC-Pmix A4 and FDC-Pmix 15s. Thus, the level of virus binding was correlated with the susceptibility of
each of these cell lines to transduction. Fibroblasts and K562 cells,
which could be efficiently transduced, bound high levels of MLV, while
no virus binding was detected in the stem cell lines with low
susceptibility to retroviral transfer.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 3.
Binding of amphotropic and 10A1 pseudotyped MLV to
fibroblasts and hematopoietic cell lines. Cells were incubated with
virus supernatants. Total virions, as well as the viral glycoprotein
gp70SU, bound to the cell surface were then stained with an
anti-gp70 antibody, followed by binding of a biotinylated secondary
antibody and streptavidin-phycoerythrin. The cells were then analyzed
on a flow cytometer.
|
|
VSV G-protein-pseudotyped retroviral vectors efficiently
transduce multipotent hematopoietic progenitor cells.
If the
lack of functional Pit1 and Pit2 retroviral receptors on FDC-Pmix was
indeed limiting retroviral transfer in stem cells, pseudotyping with
VSV G protein may improve the transduction efficiency, since VSV has a
broad host range (38). First, we demonstrated that FDC-Pmix
cells were susceptible to infection with wild-type VSV and therefore
must display the VSV receptor. We infected FDC-Pmix cells with
wild-type VSV and stained the cells with an anti-VSV G protein
antiserum after 2 days. All the cells were positive and showed a
massive cytopathic effect (data not shown). As expected, FDC-Pmix cells
were fully susceptible to infection with VSV.
A packaging cell line for VSV G-protein-pseudotyped SF1N retroviral
vector [MLV(VSV)] was established (see Materials and Methods).
As a control, the same retroviral vector was packaged in the
amphotropic
packaging cell line GP+Am12. Transduction efficiency
was determined
with the amphotropic and MLV(VSV) vectors.
Approximate equivalent
efficiencies of transfer to both stem cells and
fibroblasts were
observed with MLV(VSV), in contrast to the 100-fold
reduction
in stem cell transduction when the same vector was
pseudotyped
in amphotropic retroviral particles (Fig.
4). At lower MOIs, transduction
with
MLV(VSV) was generally found to be even more efficient in
stem cells
than in fibroblasts. The minor reduction of transfer
efficiency with
MLV(VSV) vectors at higher MOIs was accompanied
by an up to fourfold
reduction in the cloning efficiency of cells
incubated with the
pseudotyped vector (data not shown). This is
most likely to be due
to cytotoxicity of the VSV G protein in
concentrated inoccula.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Transduction of fibroblasts and FDC-Pmix cells with an
amphotropic and a VSV G protein-pseudotyped vector. Cells were
transduced at different MOIs with a retroviral vector containing
neo packaged in the amphotropic packaging cell line GP+Am12
(A) or as VSV G-protein pseudotypes in the packaging line 293gp2 (B).
Transduction efficiencies were calculated as the ratio of
G418-resistant cell clones to the number of unselected clones. Solid
circles, SC-1 fibroblasts; open circles, cell line mentioned in the
figure.
|
|
 |
DISCUSSION |
Results obtained from current gene marking and gene therapy
protocols with human hematopoietic cells have shown that the early hematopoietic stem cell is restrictive to efficient retroviral transduction (21;; reviewed in reference
4). By analogy, a similar restriction is observed
when multipotent FDC-Pmix stem cells are infected with amphotropic
retrovirus, in contrast to more mature murine and human hematopoietic
progenitors, which are permissive for efficient infection
(5). We show here that this restriction is extended to
10A1-pseudotyped vectors that use the related Pit1 receptor, while
vectors pseudotyped by VSV G protein transduced FDC-Pmix efficiently.
Moreover, binding of 10A1 and A-MLV gp70SU to FDC-Pmix
could not be detected. Therefore, retroviral gene transfer with 10A1 or
amphotropic pseudotyped MLV vectors was found to be restricted at the
receptor level.
Although no binding to FDC-Pmix was detected, gp70SU bound
to the more mature FDC-P1 and K562. These findings are in agreement with data for primary progenitor cells. Human bone marrow
CD34+ CD38
cells are enriched for long-term
repopulating cells and can bind amphotropic MLV only after stimulation
with growth factors. Nevertheless, binding is readily detected in the
more mature CD34+ CD38+ cells (9).
Moreover, a fraction of mouse bone marrow cells enriched for long-term
repopulating cells were shown to express low levels of mRNA encoding
amphotropic receptor (Pit2) (27). Although these studies
suggest that the lack of virus binding to FDC-Pmix could be due to a
low level of receptor, data so far have been circumstantial. Several
studies have shown that low MLV receptor expression does not
necessarily correlate with a low susceptibility to infection
(39). Our observation that FDC-P1 cells bind less
gp70SU but are transduced almost as efficiently as
fibroblasts is in agreement with those studies. An additional limiting
factor may be necessary for efficient transduction. Although
cells that do not bind virus are expected to be resistant to infection,
receptor expression of FDC-Pmix could be below detection limit but
sufficiently high to support virus entry. However, the
improvement of transfer efficiency with VSV G-protein pseudotypes shown
here is a clear proof that lack of a functional receptor on stem cells
indeed restricts transduction.
Our data indicate that the lack of a functional retrovirus receptor may
include not only Pit2 but also other members of this receptor family,
such as the GALV receptor Pit1. The lack of transduction of the
hematopoietic stem cell lines was, however, unexpected, because
previous studies suggested that retroviral pseudotypes, which use
Pit1, might have improved transfer efficiency in hematopoietic stem cells. Pit1 is highly expressed in bone marrow and induces stem
cell leukemia in mice (20). This indicates that 10A1 may have a preferential tropism for stem cells (31). Moreover,
infection of CD34+ progenitor and long-term culture
initiating cells with MLV vectors pseudotyped with the
gp70SU protein of GALV led to a slight (two- to fourfold)
improvement of transduction efficiency, but these studies failed to
determine if hematopoietic stem cells were transduced (37).
In contrast, we could not detect binding of 10A1 to FDC-Pmix cells, and
transduction was not improved by pseudotyping with 10A1 surface
proteins. These data clearly show that FDC-Pmix cells lack not only
functional amphotropic receptor (Pit2) but also a functional mouse
homolog of the GALV receptor (Pit1). These two receptors have over 60% amino acid identity and are presumed to have very similar topology in
the membrane. Both function as phosphate symporters and are homologous
to the phosphate permease of Neurospora crassa (20, 24,
25). Little is known about the transcriptional regulation of this
family; however, the expression levels of Pit2 have been shown to be
regulated in a tissue- and developmental stage-specific manner
(20, 33). It would not be unexpected if Pit1 and Pit2 are
regulated similarly in certain cell types.
In contrast to 10A1 pseudotypes, VSV pseudotypes of MLV efficiently
transduced FDC-Pmix. This clearly shows that transduction of FDC-Pmix
by 10A1 (or A-MLV) pseudotypes is reduced due to a lack of functional
receptor. Accordingly, binding of virus to the receptor was
found to be reduced. Since te VSV G protein also mediates penetration
of virus, we cannot exclude that virus penetration is also
restricted in the case of 10A1 or A-MLV pseudotypes. At lower MOIs,
transduction by VSV G pseudotypes tended to be even more efficient in
FDC-Pmix than in fibroblasts, but at MOIs above 10
3, the transduction efficiency of FDC-Pmix was slightly
lower. A possible explanation for this reduction may be a cytotoxic
effect of the VSV G protein in concentrated vector preparations. In
support of this theory, cloning efficiency was reduced after
transduction with MLV(VSV) pseudotypes but not with amphotropic
vectors.
In agreement with our study, a higher transduction efficiency was
achieved in human CD34+ progenitor cells with a VSV G
protein-pseudotyped lentivirus vector than with the amphotropic
pseudotype, although transfer to early progenitors was not studied
separately (2). In one study, CD34+
CD38
cells, which are enriched for stem cells, could not
be transduced with a VSV G protein-pseudotyped vector (1).
Although this seemingly contradicts the results of our study, it may
have a simple explanation. The CD34+
CD38
cells did not cycle during transduction, and
retroviral gene transfer is known to be restricted in quiescent cells,
due to an inhibition of nuclear transport of the
preintegration complex (34). In contrast, FDC-Pmix cells
propagate readily in vitro and are not subject to this preintegration
block.
The hematopoietic stem cell is the target of several gene therapy
protocols. The work presented here demonstrates that the currently used
packaging systems may be insufficient to transduce this cell population
but that VSV(MLV) pseudotypes can. To date, the development of
efficient packaging systems for the VSV G-protein pseudotypes has been
impeded by the cytotoxicity of the G protein. We are therefore testing
other viral surface proteins that pseudotype MLV for their ability to
mediate virus entry into hematopoietic cells. This work, together with
the development of culture conditions under which primary human
hematopoietic stem cells can be expanded (32), will
considerably improve gene transfer and thus allow successful gene
therapy in hematopoietic cells.
 |
ACKNOWLEDGMENTS |
We thank B. Schaefer and L. H. Evans for providing the
anti-gp70 goat serum and the MAb 83A25, respectively. The SF1N vector was supplied by C. Baum, whom we also thank for critical discussions.
This work was supported by grant 0310718 from the Bundesministerium
für Bildung und Familie. It was also supported in part by the
National Cancer Institute, DHHS, under contract to ABL. The
Heinrich-Pette-Institut is financially supported by Freie und
Hansestadt Hamburg and Bundesministerium für Gesundheit.
 |
FOOTNOTES |
*
Corresponding author. Mailing address:
Heinrich-Pette-Institut, Martinistr. 52, D-20251 Hamburg, Germany.
Phone: 49-40-48051274. Fax: 49-40-48051187. E-mail:
laer{at}hpi.uni-hamburg.de.
 |
REFERENCES |
| 1.
|
Agrawal, Y. P.,
R. S. Agrawal,
A. M. Sinclair,
D. Young,
M. Maruyama,
F. Levine, and A. D. Ho.
1996.
Cell-cycle kinetics and VSV-G pseudotyped retroviral-mediated gene transfer in blood-derived CD34+ cells.
Exp. Hematol.
24:738-747[Medline].
|
| 2.
|
Akkina, R. K.,
R. M. Walton,
M. L. Chen,
Q.-X. Li,
V. Planelles, and I. S. Y. Chen.
1996.
High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G.
J. Virol.
70:2581-2585[Abstract].
|
| 3.
|
Baum, C.,
S. Hegewisch Becker,
H. G. Eckert,
C. Stocking, and W. Ostertag.
1995.
Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells.
J. Virol.
69:7541-7547[Abstract].
|
| 4.
| Baum, C., C. Stocking, T. Wagener, H.-G.
Eckert, and W. Ostertag. Gene transfer and transgene expression in
hematopoietic cells. In M. Strauss and W. Barranger (ed.),
Concepts of gene therapy, in press. Walter de Gruyter, Berlin, Germany.
|
| 5.
|
Beck-Engeser, G.,
C. Stocking,
U. Just,
L. Albritton,
M. Dexter,
E. Spooncer, and W. Ostertag.
1991.
Retroviral vectors related to the myeloproliferative sarcoma virus allow efficient expression in hematopoietic stem and precursor cell lines, but retroviral infection is reduced in more primitive cells.
Hum. Gene Ther.
2:61-70[Medline].
|
| 6.
|
Bodine, D. M.,
T. Moritz,
R. E. Donahue,
B. D. Luskey,
S. W. Kessler,
D. I. Martin,
S. H. Orkin,
A. W. Nienhuis, and D. A. Williams.
1993.
Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells.
Blood
82:1975-1980[Abstract/Free Full Text].
|
| 7.
|
Boettiger, D.,
S. Anderson, and T. M. Dexter.
1984.
Effect of src infection on long-term marrow cultures: increased self-renewal of hemopoietic progenitor cells without leukemia.
Cell
36:763-773[Medline].
|
| 8.
|
Brenner, M. K.,
J. M. Cunningham,
B. P. Sorrentino, and H. E. Heslop.
1995.
Gene transfer into human hemopoietic progenitor cells.
Br. Med. Bull.
51:167-191[Abstract/Free Full Text].
|
| 9.
|
Crooks, G. M., and D. B. Kohn.
1993.
Growth factors increase amphotropic retrovirus binding to human CD34+ bone marrow progenitor cells.
Blood
82:3290-3297[Abstract/Free Full Text].
|
| 10.
|
Dexter, T. M.,
J. Garland,
D. Scott,
E. Scolnick, and D. C. Metcalf.
1980.
Growth of factor-dependent hemopoietic precursor cell lines.
J. Exp. Med.
152:1036-1047[Abstract/Free Full Text].
|
| 11.
|
Dirks, W.,
M. Wirth, and H. Hauser.
1993.
Dicistronic transcription units for gene expression in mammalian cells.
Gene
128:247-249[Medline].
|
| 12.
|
Dunbar, C. E.,
M. Cottler Fox,
J. A. O'Shaughnessy,
S. Doren,
C. Carter,
R. Berenson,
S. Brown,
R. C. Moen,
J. Greenblatt,
F. M. Stewart, et al.
1995.
Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.
Blood
85:3048-3057[Abstract/Free Full Text].
|
| 13.
|
Eckert, H.-G.,
M. Stockschläger,
U. Just,
S. Hegewisch-Becker,
M. Grez,
A. Uhde,
A. Zander,
W. Ostertag, and C. Baum.
1996.
High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors.
Blood
88:3407-3415[Abstract/Free Full Text].
|
| 14.
|
Evans, L. H.,
R. P. Morrison,
F. G. Malik,
J. Portis, and W. J. Britt.
1990.
A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses.
J. Virol.
64:6176-6183[Abstract/Free Full Text].
|
| 15.
|
Ford, A. M.,
C. A. Bennett,
L. E. Healy,
E. Navarro,
E. Spooncer, and M. F. Greaves.
1992.
Immunoglobulin heavy-chain and CD3 delta-chain gene enhancers are DNase I-hypersensitive in hemopoietic progenitor cells.
Proc. Natl. Acad. Sci. USA
89:3424-3428[Abstract/Free Full Text].
|
| 16.
|
Gallione, C. J., and J. K. Rose.
1983.
Nucleotide sequence of a cDNA clone encoding the entire glycoprotein from the New Jersey serotype of vesicular stomatitis virus.
J. Virol.
46:162-169[Abstract/Free Full Text].
|
| 17.
|
Just, U.,
C. Stocking,
E. Spooncer,
T. M. Dexter, and W. Ostertag.
1991.
Expression of the GM-CSF gene after retroviral transfer in hematopoietic stem cell lines induces synchronous granulocyte-macrophage differentiation.
Cell
64:1163-1173[Medline].
|
| 18.
|
Kadan, M. J.,
S. Sturm,
W. F. Andersen, and M. A. Eglitis.
1992.
Detection of receptor-specific murine leukemia virus binding to cells by immunofluorescence analysis.
J. Virol.
66:2281-2287[Abstract/Free Full Text].
|
| 19.
|
Karasuyama, H., and F. Melchers.
1988.
Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2,3,4 or 5, using modified cDNA expression vectors.
Eur. J. Immunol.
18:97-104[Medline].
|
| 20.
|
Kavanaugh, M. P.,
D. G. Miller,
W. Zhang,
W. Law,
S. L. Kozak,
D. Kabat, and A. D. Miller.
1996.
Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retroviruses are inducible sodium-dependent phosphate symporters.
Proc. Natl. Acad. Sci. USA
91:7071-7075[Abstract/Free Full Text].
|
| 21.
|
Larochelle, A.,
J. Vormoor,
H. Hanenberg,
J. C. Y. Wang,
M. Bhatia,
T. Lapidot,
T. Moritz,
B. Murdoch,
X. L. Xiao,
I. Kato,
D. A. Williams, and J. E. Dick.
1996.
Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy.
Nat. Med.
2:1329-1337[Medline].
|
| 22.
|
Markowitz, D.,
S. Goff, and A. Bank.
1988.
Construction and use of a safe and efficient amphotropic packaging cell line.
Virology
167:400-406[Medline].
|
| 23.
|
Miller, A. D., and F. Cheng.
1996.
Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry.
J. Virol.
70:5564-5571[Abstract/Free Full Text].
|
| 24.
|
Miller, D. G.,
R. H. Edward, and A. D. Miller.
1994.
Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus.
Proc. Natl. Acad. Sci. USA
91:78-82[Abstract/Free Full Text].
|
| 25.
|
Miller, D. G., and A. D. Miller.
1994.
A family of retroviruses that utilize related phosphate transporters for cell entry.
J. Virol.
68:8270-8276[Abstract/Free Full Text].
|
| 26.
|
Münk, C.,
J. Löhler,
V. Prassolov,
U. Just,
M. Stockschläger, and C. Stocking.
1997.
Amphotropic murine leukemia viruses induce spongiform encephalopathy.
Proc. Natl. Acad. Sci. USA
94:5837-5842[Abstract/Free Full Text].
|
| 27.
|
Orlic, D.,
L. J. Girard,
C. T. Jordan,
S. M. Andersen,
A. P. Cline, and D. M. Bodine.
1996.
The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction.
Proc. Natl. Acad. Sci. USA
93:11097-11102[Abstract/Free Full Text].
|
| 28.
|
Osawa, M.,
K. Hanada,
H. Hamada, and H. Nakauchi.
1996.
Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic cell.
Science
273:242-245[Abstract].
|
| 29.
|
Ott, D.,
R. Friedrich, and A. Rein.
1990.
Sequence analysis of amphotropic and 10A1 murine leukemia viruses: close relationship to mink cell focus-inducing viruses.
J. Virol.
64:757-766[Abstract/Free Full Text].
|
| 30.
|
Ott, D., and A. Rein.
1992.
Basis for receptor specificity of nonecotropic murine leukemia virus surface glycoprotein gp70SU.
J. Virol.
66:4632-4638[Abstract/Free Full Text].
|
| 31.
|
Ott, D. E.,
J. Keller, and A. Rein.
1994.
10A1 MULV induces leukemia that expresses hematopoietic stem cell markers by a mechanism that includes fli-1 integration.
Virology
205:563-568[Medline].
|
| 32.
|
Petzer, A. L.,
D. E. Hogge,
P. M. Lansdorp,
D. S. Reid, and C. J. Eaves.
1996.
Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium.
Proc. Natl. Acad. Sci. USA
93:1470-1474[Abstract/Free Full Text].
|
| 33.
|
Richardson, C., and A. Bank.
1996.
Developmental-stage-specific expression and regulation of amphotropic retroviral receptor in hematopoietic cells.
Mol. Cell. Biol.
16:4240-4247[Abstract].
|
| 34.
|
Roe, T.,
T. Reynolds,
G. Yu, and P. O. Brown.
1993.
Integration of murine leukemia virus DNA depends on mitosis.
EMBO J.
12:2099-2108[Medline].
|
| 35.
|
Simon, I.,
J. Löhler, and R. Jaenisch.
1982.
Virus-specific transcription and translation in organs of BALB/Mo mice: comparative study using quantitative hybridization, in situ hybridization, and immunocytochemistry.
Virology
120:106-121[Medline].
|
| 36.
|
van Beusechem, V. W.,
A. Kukler,
P. J. Heidt, and D. Valerio.
1992.
Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells.
Proc. Natl. Acad. Sci. USA
89:7640-7644[Abstract/Free Full Text].
|
| 37.
|
von Kalle, C.,
H.-P. Kiem,
S. Goehle,
B. Darovsky,
S. Heimfeld,
B. Torok-Storb,
R. Storb, and F. G. Schuening.
1994.
Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector.
Blood
84:2890-2897[Abstract/Free Full Text].
|
| 38.
|
Wagner, R. R., and J. K. Rose.
1996.
Rhabdoviridae: the viruses and their replication, p. 1121-1136. In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology.
Lippincott-Raven, Philadelphia, Pa.
|
| 39.
|
Wang, H.,
R. Paul,
R. E. Burgeson,
D. R. Keene, and D. Kabat.
1991.
Plasma membrane receptors for ecotropic murine retroviruses require a limiting accessory factor.
J. Virol.
65:6468-6477[Abstract/Free Full Text].
|
J Virol, February 1998, p. 1424-1430, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Prassolov, V., Hein, S., Ziegler, M., Ivanov, D., Münk, C., Löhler, J., Stocking, C.
(2001). Mus cervicolor Murine Leukemia Virus Isolate M813 Belongs to a Unique Receptor Interference Group. J. Virol.
75: 4490-4498
[Abstract]
[Full Text]
-
Miletic, H., Bruns, M., Tsiakas, K., Vogt, B., Rezai, R., Baum, C., Kühlke, K., Cosset, F.-L., Ostertag, W., Lother, H., von Laer, D.
(1999). Retroviral Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus. J. Virol.
73: 6114-6116
[Abstract]
[Full Text]
-
MacNeill, E. C., Hanenberg, H., Pollok, K. E., van der Loo, J. C. M., Bierhuizen, M. F. A., Wagemaker, G., Williams, D. A.
(1999). Simultaneous Infection with Retroviruses Pseudotyped with Different Envelope Proteins Bypasses Viral Receptor Interference Associated with Colocalization of gp70 and Target Cells on Fibronectin CH-296. J. Virol.
73: 3960-3967
[Abstract]
[Full Text]
-
Lavillette, D., Maurice, M., Roche, C., Russell, S. J., Sitbon, M., Cosset, F.-L.
(1998). A Proline-Rich Motif Downstream of the Receptor Binding Domain Modulates Conformation and Fusogenicity of Murine Retroviral Envelopes. J. Virol.
72: 9955-9965
[Abstract]
[Full Text]